Biomedical Engineering Reference
In-Depth Information
54. Ribas, A,
. (2011). BRIM-2: an open-label, multicenter phase II
study of vemurafenib in previously treated patients with BRAFV600E
mutation-positive melanoma,
et al
J Clin Oncol
.,
29
, suppl.8509.abstract.
55. Schwartz, GK,
. (2009). A phase-I study of XL281, a selective oral
RAF kinase inhibitor, in patients with advanced solid tumors,
et al
J Clin
, abstract 3513
56. Kefford, R,
Oncol
.,
27
. (2010). Phase I/II study of GSK2118436, a selective
inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic
melanoma and other solid tumors,
et al
J Clin Oncol
.,
28
, abstract 8503.
57. Paraiso, K,
. (2010). Recovery of phospho-ERK activity allow
melanoma cells to escape from BRAF inhibitor therapy,
et al
British Journal
, pp. 1724-1730.
58. Solit, D and Rosen, N. (2011). Resistance to BRAF Inhibition in
Melanomas,
of Cancer
,
102
N Engl J Med
.,
64
, pp. 772-774.
59. Lorusso, PM,
. (2005). Phase I and pharmocodynamic study of the
oral MEK inhibitor CI-1040 in patients with advanced malignancies,
et al
J
Clin Oncol
.,
23
, pp. 5281-5293.
60. Rinehart, J,
. (2004). Multicenter phase II study of the oral MEK
inhibitor, CI-1040 in patients with advanced non-small-cell lung,
breast, colon, and pancreatic cancer,
et al
J Clin Oncol
.,
22
, pp. 4456-4462.
61. Lorusso,
. (2010). Phase I pharmacokinetic and
pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-
0325901 in patients with advanced cancers,
PM,
et
al
Clin Cancer Res
.,
16
, pp.
1924-1937.
62. Adjei, AA,
. (2008). Phase I pharmacokinetic and pharmacodynamic
study of the oral, small-molecule mitogen-activated protein kinase
kinase ½ inhibitor AZD6244 (ARRY-142886) in patients with advanced
cancers,
et al
J Clin Oncol.,
26
, pp. 2139-2146.
63. Dummer,
. (2008). AZD6244 (ARRY-142886) versus
temozolomide (TMZ) in patients (pts) with advanced melanoma: an
open-label, randomized, multicenter, phase II study,
R,
et
al
J Clin Oncol
.,
26
,
abstract 9033.
64. da Rocha Dias, S,
. (2005). Activated B-RAF is a Hsp90 client
protein that is targeted by the anticancer drug 17-allylamino-17-
demethoxygeldanamycin,
et al
Cancer Res.,
65
, pp. 10686-10691.
65. Villanueva, J,
. (2010). Acquired Resistance to BRAF Inhibitors
Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by
Cotargeting MEK and IGF-1R/P13K,
et al
Cancer Cell
,
18
, pp. 683-695.
